At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 8 enrolled
Drug / intervention
Epigallocatechin gallate +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Polyphenol Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism During Graded Exercise in Man.
In Brief
A Phase 4 clinical trial evaluating Epigallocatechin gallate and Placebo for EGCG Influence on Catecholamine Metabolism. Completed, enrolled 8 participants.
Detailed Summary
The aim of this study was to explore the impact of acute ingestion of the polyphenol epigallocatechin galate (EGCG) on catecholamine, catecholamine metabolite, systemic metabolic and cardio-vascular variables across a range of exercise intensities during graded cycle exercise in man.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
Primary CompletionJan 2016
Study CompletionFeb 2016
First PostedJun 2017
TodayJul 2026
First PostedJun 27, 2017
Enrollment StartSep 1, 2015
Primary CompletionJan 1, 2016
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.0 years ago
Interventions
Epigallocatechin gallatedietary
Placebodietary
1450mg Corn Flour